Dark Forest Capital Management LP Makes New $818,000 Investment in Certara, Inc. (NASDAQ:CERT)

Dark Forest Capital Management LP purchased a new position in shares of Certara, Inc. (NASDAQ:CERT) during the 4th quarter, HoldingsChannel reports. The firm purchased 76,776 shares of the company’s stock, valued at approximately $818,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CERT. State of Tennessee Department of Treasury increased its position in Certara by 28.4% during the fourth quarter. State of Tennessee Department of Treasury now owns 50,775 shares of the company’s stock worth $541,000 after buying an additional 11,224 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Certara by 473.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 27,172 shares of the company’s stock valued at $289,000 after acquiring an additional 22,430 shares during the last quarter. First Trust Advisors LP bought a new position in shares of Certara in the 4th quarter valued at approximately $140,000. Marshall Wace LLP lifted its holdings in Certara by 11.3% in the 4th quarter. Marshall Wace LLP now owns 47,855 shares of the company’s stock worth $510,000 after purchasing an additional 4,855 shares during the last quarter. Finally, Gamco Investors INC. ET AL bought a new stake in Certara during the fourth quarter worth approximately $133,000. Institutional investors own 73.96% of the company’s stock.

Certara Stock Up 1.2 %

NASDAQ CERT opened at $14.42 on Friday. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $17.94. The stock has a market cap of $2.33 billion, a PE ratio of -72.10, a PEG ratio of 9.29 and a beta of 1.64. The firm has a 50-day simple moving average of $11.65 and a 200 day simple moving average of $11.55. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Wall Street Analyst Weigh In

CERT has been the subject of a number of analyst reports. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Barclays decreased their price target on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. KeyCorp lifted their price objective on Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. Robert W. Baird increased their target price on Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Finally, TD Cowen assumed coverage on Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.17.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.